Hikma Pharmaceuticals (LON:HIK) had its price objective raised by JPMorgan Chase from GBX 1,000 ($14.04) to GBX 1,050 ($14.74) in a report released on Thursday, March 15th. JPMorgan Chase currently has a neutral rating on the stock.
Several other research analysts also recently issued reports on HIK. Peel Hunt reissued a hold rating and set a GBX 1,390 ($19.51) price objective on shares of Hikma Pharmaceuticals in a research report on Wednesday, November 15th. Morgan Stanley reissued an equal weight rating and set a GBX 1,100 ($15.44) price objective on shares of Hikma Pharmaceuticals in a research report on Friday, December 1st. Jefferies Group raised their target price on shares of Hikma Pharmaceuticals from GBX 1,045 ($14.67) to GBX 1,074 ($15.08) and gave the stock a hold rating in a research note on Monday, December 4th. Numis Securities reiterated a buy rating and issued a GBX 1,300 ($18.25) price objective on shares of Hikma Pharmaceuticals in a research note on Wednesday, December 20th. Finally, Barclays cut shares of Hikma Pharmaceuticals to an underweight rating and reduced their price objective for the company from GBX 1,500 ($21.06) to GBX 800 ($11.23) in a research note on Thursday, March 1st. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of GBX 1,083.20 ($15.20).
Shares of LON HIK traded up GBX 19 ($0.27) during mid-day trading on Thursday, reaching GBX 1,204 ($16.90). The company had a trading volume of 605,305 shares, compared to its average volume of 822,138. Hikma Pharmaceuticals has a 52-week low of GBX 814.20 ($11.43) and a 52-week high of GBX 2,346 ($32.93).
The business also recently announced a dividend, which will be paid on Thursday, May 24th. Investors of record on Thursday, April 5th will be issued a $0.23 dividend. This represents a yield of 1.47%. This is an increase from Hikma Pharmaceuticals’s previous dividend of $0.22. The ex-dividend date is Thursday, April 5th.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/hikma-pharmaceuticals-hik-pt-raised-to-gbx-1050-at-jpmorgan-chase-co.html.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.